Combining systemic therapy with local ablative treatments for certain lung cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 2 pragmatic study evaluates the clinical benefit of continuing systemic therapy while adding locally ablative therapies for patients with oligoprogressive solid tumors. The primary objective is to measure the time to treatment failure after the addition of ablative therapy. Participants will receive either stereotactic ablative radiotherapy or interventional radiology ablation therapy, depending on the treating physician's discretion. The study will follow participants for up to 5 years to assess disease control and treatment outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Must have one of the following histologically and/or biochemically confirmed genitourinary malignancies:

   1. Cohort A: Non-small cell cancer
   2. Cohort B: Small cell cancer
2. Provision of signed and dated informed consent form.
3. Stated willingness to comply with all study procedures and availability for the duration of the study.
4. Age ≥18 years at time of consent.
5. Currently on systemic therapy and a candidate to continue their current line of systemic therapy with no more than a planned 30-day break to allow for local ablative therapy.
6. ≥ 1 line of systemic therapy for metastatic disease with ≥ 3 months of clinical benefit on most recent line of systemic therapy prior to the development of new metastatic lesions. \[Clinical benefit: Treating provider assessment that majority of the tumor burden is stable on current systemic treatment and not requiring an immediate change in systemic treatment\]
7. ≤ 5 progressing or new metastatic lesions.
8. All progressing or new metastatic lesions can be safely treated with locally ablative therapies at discretion of treating radiation oncologist and/ interventional radiologist.

Exclusion Criteria:

1. Medical comorbidities precluding locally ablative therapies.
2. History of treatment related toxicities that limit or prohibit application of locally ablative therapies.
3. Progressing intracranial lesions.

Where it's running

• University of California, Davis
  Sacramento, California, United States Recruiting

Study contacts

• Principal investigator: Xiao Zhao, MD — University of California, Davis
• Study coordinator: Office of Clinical Research
• Email: OCRReferral@health.ucdavis.edu
• Phone: 916-382-6970

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• First-in-human test of HH160 in people with advanced solid tumors

  HH160 is being tested to see if it is safe and how it behaves in the body, to see if it has early signs of helping various advanced cancers in adults.

  Recruiting at 3 sites Phase 1 Huahui Health · Waratah, New South Wales and 2 other locations · NCT07623369

• CAIX-targeted 18F-T2 PET/CT imaging in solid tumors

  This study tests a CAIX-specific radioactive tracer to see if PET/CT can help visualize solid tumors and checks safety and radiation exposure in adults with certain cancers.

  Recruiting Peking University First Hospital · Beijing, Beijing Municipality · NCT07557225

• HLX43 with Serplulimab in advanced lung cancer

  This study tests whether HLX43 given with serplulimab can help adults with advanced NSCLC or SCLC who have had prior chemotherapy and immunotherapy.

  Recruiting at 10 sites Phase 2 Shanghai Henlius Biotech · Hefei, Anhui and 9 other locations · NCT07253142

• Combination of YL201 and ivonescimab (AK112) for advanced solid tumors

  This trial will test whether combining YL201 and ivonescimab (AK112) helps people with advanced solid tumors, including non‑small cell and small cell lung cancer.

  Recruiting Phase 1/2 MediLink Therapeutics (Suzhou) Co., Ltd. · Guangzhou, Guangdong · NCT07208773

• Cirtuvivint plus irinotecan for relapsed small-cell lung cancer

  This trial will test whether adding cirtuvivint to irinotecan helps people with relapsed small-cell lung cancer respond better and live longer.

  Recruiting Phase 1/2 Washington University School of Medicine · St Louis, Missouri · NCT07155200

• GV20-0251 treatment for adults with advanced solid tumors

  This study will test GV20-0251 to see if it helps adults with advanced solid tumors that have stopped responding to approved therapies.

  Recruiting at 3 sites Phase 1/2 GV20 Therapeutics · Beijing, Beijing Municipality and 2 other locations · NCT07070518

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.